Merck Reports Three-Year KEYNOTE-590 Data for Keytruda in Esophageal Cancer

Merck today presented three-year overall survival data from the Phase 3 KEYNOTE-590 trial evaluating Keytruda (pembrolizumab) plus chemotherapy in patients with locally advanced or metastatic esophageal cancer or gastroesophageal junction adenocarcinoma. The data showed that the overall survival benefit of Keytruda was maintained at three years.